Clinical Trial Update: Bevacizumab In Hereditary Hemorrhagic Telangiectasia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of bevacizumab for hereditary hemorrhagic telangiectasia is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Hanny Al-Samkari, MD | Conditions: Hereditary Hemorrhagic Telangiectasia | Phase 2 | Status: ACTIVE_NOT_RECRUITING